BR112018071208A2 - preparação inalada de ácido isoglicirrízico ou sal do mesmo, e uso na preparação de fármacos para tratar doenças do sistema respiratório - Google Patents
preparação inalada de ácido isoglicirrízico ou sal do mesmo, e uso na preparação de fármacos para tratar doenças do sistema respiratórioInfo
- Publication number
- BR112018071208A2 BR112018071208A2 BR112018071208-6A BR112018071208A BR112018071208A2 BR 112018071208 A2 BR112018071208 A2 BR 112018071208A2 BR 112018071208 A BR112018071208 A BR 112018071208A BR 112018071208 A2 BR112018071208 A2 BR 112018071208A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- isoglycyrrizic
- drugs
- salt
- acid
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610237175 | 2016-04-15 | ||
| CN201610237175.3 | 2016-04-15 | ||
| PCT/CN2017/080583 WO2017177966A1 (zh) | 2016-04-15 | 2017-04-14 | 异甘草酸或其盐的吸入制剂及其在制备治疗呼吸系统疾病药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071208A2 true BR112018071208A2 (pt) | 2019-02-12 |
Family
ID=60042326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071208-6A BR112018071208A2 (pt) | 2016-04-15 | 2017-04-14 | preparação inalada de ácido isoglicirrízico ou sal do mesmo, e uso na preparação de fármacos para tratar doenças do sistema respiratório |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190117568A1 (enExample) |
| EP (1) | EP3443954A4 (enExample) |
| JP (2) | JP7166929B2 (enExample) |
| KR (1) | KR102410183B1 (enExample) |
| CN (2) | CN111920785B (enExample) |
| AU (1) | AU2017251548B2 (enExample) |
| BR (1) | BR112018071208A2 (enExample) |
| EA (1) | EA201892350A1 (enExample) |
| MX (1) | MX394106B (enExample) |
| MY (1) | MY204600A (enExample) |
| PH (1) | PH12018502195A1 (enExample) |
| SG (2) | SG11201809042SA (enExample) |
| WO (1) | WO2017177966A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119345161A (zh) * | 2024-12-25 | 2025-01-24 | 江苏长泰药业股份有限公司 | 一种丙酮酸钠雾化吸入制剂及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891221A (en) * | 1988-11-23 | 1990-01-02 | Edward Shanborm | Whole blood antiviral process and composition |
| WO2005004913A1 (ja) * | 2003-07-09 | 2005-01-20 | Anges Mg, Inc. | デコイを含む薬学的組成物およびその使用方法 |
| JP2009513529A (ja) * | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
| CN101023953B (zh) * | 2006-07-24 | 2010-05-12 | 南开大学 | 治疗支气管哮喘的组合物 |
| CN101190232B (zh) * | 2006-11-30 | 2011-08-17 | 江苏正大天晴药业股份有限公司 | 一种注射用异甘草酸镁冻干粉针剂及其制备方法 |
| JP2008222682A (ja) * | 2007-03-15 | 2008-09-25 | Kumamoto Univ | 線維化肺疾患治療薬、気道粘液分泌細胞過形成抑制剤および気道塞栓治療薬 |
| CN101396368B (zh) * | 2007-09-29 | 2010-12-01 | 江苏正大天晴药业股份有限公司 | 异甘草酸或其盐在制备治疗过敏性鼻炎药物中的应用 |
| CN101669962A (zh) * | 2009-09-18 | 2010-03-17 | 杭州市第六人民医院 | 复合甘草酸氨基酸注射液及其制备方法和应用 |
| CA2809031C (en) * | 2010-08-25 | 2018-10-16 | Weijian Zhang | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| CN103156930A (zh) * | 2011-12-19 | 2013-06-19 | 张亚军 | 一种含芍药和甘草提取物的呼吸道给药制剂 |
| SG11201404522VA (en) | 2012-03-13 | 2014-10-30 | Respivert Ltd | Crystalline pi3 kinase inhibitors |
| CN102920936A (zh) * | 2012-09-17 | 2013-02-13 | 陈泉生 | 一种治疗呼吸道疾病的吸盐物及其制作方法 |
| CN104042573A (zh) * | 2014-06-03 | 2014-09-17 | 青岛市市立医院 | 一种异甘草酸镁冻干粉针剂及其制备方法 |
| CN106237297A (zh) * | 2016-08-30 | 2016-12-21 | 吉林紫鑫药业股份有限公司 | 一种用于治疗慢性支气管炎的药物组合物 |
-
2017
- 2017-04-14 SG SG11201809042SA patent/SG11201809042SA/en unknown
- 2017-04-14 EP EP17781942.2A patent/EP3443954A4/en active Pending
- 2017-04-14 BR BR112018071208-6A patent/BR112018071208A2/pt not_active Application Discontinuation
- 2017-04-14 CN CN202010842414.4A patent/CN111920785B/zh active Active
- 2017-04-14 EA EA201892350A patent/EA201892350A1/ru unknown
- 2017-04-14 AU AU2017251548A patent/AU2017251548B2/en active Active
- 2017-04-14 CN CN201780018629.0A patent/CN109069442B/zh active Active
- 2017-04-14 SG SG10202010192YA patent/SG10202010192YA/en unknown
- 2017-04-14 MX MX2018012461A patent/MX394106B/es unknown
- 2017-04-14 JP JP2018554375A patent/JP7166929B2/ja active Active
- 2017-04-14 MY MYPI2018703789A patent/MY204600A/en unknown
- 2017-04-14 WO PCT/CN2017/080583 patent/WO2017177966A1/zh not_active Ceased
- 2017-04-14 KR KR1020187033045A patent/KR102410183B1/ko active Active
- 2017-04-14 US US16/093,087 patent/US20190117568A1/en not_active Abandoned
-
2018
- 2018-10-12 PH PH12018502195A patent/PH12018502195A1/en unknown
-
2020
- 2020-08-07 US US16/988,289 patent/US11534398B2/en active Active
-
2021
- 2021-08-02 JP JP2021126412A patent/JP7309791B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7309791B2 (ja) | 2023-07-18 |
| CN111920785B (zh) | 2022-05-20 |
| MX2018012461A (es) | 2019-09-18 |
| US20200368158A1 (en) | 2020-11-26 |
| MY204600A (en) | 2024-09-05 |
| JP2021176903A (ja) | 2021-11-11 |
| EP3443954A1 (en) | 2019-02-20 |
| US11534398B2 (en) | 2022-12-27 |
| PH12018502195A1 (en) | 2019-09-23 |
| SG10202010192YA (en) | 2020-11-27 |
| US20190117568A1 (en) | 2019-04-25 |
| CN109069442B (zh) | 2020-09-04 |
| AU2017251548B2 (en) | 2022-02-17 |
| EP3443954A4 (en) | 2019-11-20 |
| EA201892350A1 (ru) | 2019-06-28 |
| JP2019511556A (ja) | 2019-04-25 |
| CN109069442A (zh) | 2018-12-21 |
| KR102410183B1 (ko) | 2022-06-17 |
| WO2017177966A1 (zh) | 2017-10-19 |
| KR20180132143A (ko) | 2018-12-11 |
| AU2017251548A1 (en) | 2018-11-15 |
| JP7166929B2 (ja) | 2022-11-08 |
| SG11201809042SA (en) | 2018-11-29 |
| CN111920785A (zh) | 2020-11-13 |
| MX394106B (es) | 2025-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
| CL2019001214A1 (es) | Composición farmacéutica, métodos para tratamiento y sus usos. | |
| BR112019000690A2 (pt) | composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide | |
| BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
| BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
| CL2018002727A1 (es) | Medicina obtenida mediante la combinación de agonista fxr y arb | |
| BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| BR112018005861A2 (pt) | derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| BR112017020039A2 (pt) | composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica | |
| BR112016020260A8 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
| BR112017013674A2 (pt) | métodos e composições para tratamento de doenças cerebrais. | |
| BR112017024304A2 (pt) | processo para a preparação de um extrato de cérebro animal | |
| BR112017013999A2 (pt) | ?composição derivada de uma bifidobactéria? | |
| BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
| PT3604304T (pt) | Composto derivado de pirrolo-piridina, método para a sua preparação e composição farmacêutica que o contém como substância ativa para prevenção ou tratamento de doenças relacionadas com proteína quinase | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112018067554A2 (pt) | formulações de testosterona e métodos de tratamento com as mesmas | |
| BR112017004035A2 (pt) | inibidores macrocíclicos de rip2 quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |